Background {#Sec1}
==========

Atrial fibrillation (AF) is the most prevalent arrhythmia observed in clinical practice, and is associated with significant morbidity and mortality in the popuation. The burden of AF increases over time mainly due to an aging population and to the increasing prevalence of cardiovascular comorbidities. However, strategies to predict and prevent AF are not fully effective \[[@CR1]\]. Diabetes mellitus (DM) is one of the strongest independent risk factors for AF incidence, conferring an approximate 40% higher risk of subsequent AF development \[[@CR2], [@CR3]\]. It also predicts the recurrence of AF following a successful direct current cardioversion \[[@CR4]\]. Moreover, DM increases the risk of developing stroke, heart failure, and cardiovascular death in patients with AF \[[@CR5]\]. Although the exact pathophysiological mechanisms linking DM and AF remain incompletely elucidated, an increasing body of evidence suggests that inflammation and oxidative stress may play an important role \[[@CR6]--[@CR8]\].

Thiazolidinediones (TZDs), a class of peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, are among the most potent insulin-sensitizing drugs \[[@CR9]\]. Apart from their anti-diabetic activity, TZDs display several pleiotropic effects including anti-inflammatory and antioxidant actions that may have potential benefits for AF prevention \[[@CR10], [@CR11]\]. However, inconsistent results have been reported regarding TZDs use and AF incidence \[[@CR12]--[@CR18]\]. In light of such conflicting data, we performed a comprehensive meta-analysis to evaluate the present evidence and investigate whether the use of TZDs confers benefits in preventing AF.

Methods {#Sec2}
=======

This systematic review was conducted according to the Quality of Reports of Meta-Analyses of Randomized Controlled Trials (QUOROM) recommendations \[[@CR19]\] and the guidelines of the Meta-analysis of Observational Studies in Epidemiology Group (MOOSE) \[[@CR20]\].

Inclusion criteria {#Sec3}
------------------

The studies considered for this meta-analysis were either randomized clinical trials (RCTs) or observational studies that investigated the potential effects of TZDs on AF. The inclusion criteria were as follows: *RCTs*: 1) randomized controlled human trials with a parallel design; 2) comparison of TZDs with control; 3) collecting data on new or recurrent AF during follow-up. *Observational Studies*: 1) comparison of TZDs with control; 2) evaluating new or recurrent AF as an outcome. In the studies of interventions with TZDs no limit in the length of follow-up period was set due to the paucity of relevant studies.

Search strategies {#Sec4}
-----------------

A systematic literature search was performed by two investigators (Z. Z. and X. Z.) using the online databases of PubMed and Embase to identify relevant studies published before December 2016. The following key terms were used: "thiazolidinediones", "pioglitazone", "rosiglitazone", "troglitazone", and "atrial fibrillation". Both investigators independently evaluated the search results and identified potential studies for further assessment. Disagreements were resolved by a third reviewer (T. L.).

Quality assessment and data extraction {#Sec5}
--------------------------------------

As quality scoring in meta-analyses of RCTs and observational studies is controversial, several key points of study quality were assessed according to a critical review checklist of Wynn et al. \[[@CR21]\]. The key points of this checklist and quality assessments of included studies are listed in Table [1](#Tab1){ref-type="table"}.Table 1Quality assessments of included studiesStudy, yearStudy\
typeRandomisation\
MethodBlindingEligibility criteria reportedStudy Population representative of normal practiceMethod of follow-up properly definedEqual follow-up between groupsWas loss to follow-up\
reported or explainedProspective\
recruitmentConsecutive\
recruitmentPROactive, 2005 \[[@CR12]\]RCTRandomised permuted blocksDoubleYesYesYesYesYesYesYesAnglade, 2007 \[[@CR13]\]Case\
controlNANAYesYesYesYesNo loss to follow-upNoYesRECORD, 2009 \[[@CR14]\]RCTRandompermuted\
blocksNoneYesYesYesYesYesYesYesGu, 2011 \[[@CR15]\]CohortNANAYesYesYesYesNo loss to follow-upYesYesChao, 2012 \[[@CR16]\]Case\
controlNANAYesYesYesYesNo loss to follow-upNoYesLiu, 2014 \[[@CR17]\]RCTComputerDoubleYesYesYesYesNo loss to follow-upYesYesPallisgaard, 2016 \[[@CR18]\]CohortNANAYesYesYesYesNo loss to follow-upYesYes*Abbreviations*: *RCT* randomized controlled trial, *NA* not applicable

Two investigators (Z. Z. and X. Z.) independently extracted the relevant data using a pre-defined spreadsheets. The extracted data elements of the meta-analysis included information on the inclusion criteria, publication details, study design, follow-up duration, daily dosage of TZDs, definition of AF, methods of AF detection, baseline patient characteristics, the variables of multivariate model used in observational studies and results. Disagreements were resolved through discussion or consensus with a third reviewer (T. L.).

Statistical analysis {#Sec6}
--------------------

Results of the AF outcome are expressed as odds ratio (OR) with 95% confidence interval (CI) for each study using generic inverse-variance method. The hazard ratio value using multivariate Cox proportional hazards model in the primary study was directly considered as OR \[[@CR22]\]. Raw event numbers were extracted from the RCTs and adjusted effect estimates from the observational studies to calculate the overall effects. Statistical heterogeneity was assessed by the χ^2^ test and quantified by using the I^2^ statistic. An I^2^ \> 50% is indicative of at least moderate heterogeneity \[[@CR23]\]. A random-effects model was used. Subgroup analyses regarding AF subtypes (new onset AF or recurrent AF), different TZDs (solely pioglitazone or solely rosiglitazone), study designs (RCTs or observational studies), and different follow-up duration (\>5 years or ≤5 years) were additionally performed. Sensitivity analysis was done by removing one study at a time and checking the consequent effects on the effect estimate. Publication bias was evaluated using a funnel plot. Two-tailed *p* values of \<0.05 were considered statistically significant. The statistical analysis was performed using the Review Manager (RevMan, version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results {#Sec7}
=======

A total of 346 records were identified initially through our literature search strategy. After careful assessment, seven studies (three RCTs \[[@CR12], [@CR14], [@CR17]\] and four observational studies \[[@CR13], [@CR15], [@CR16], [@CR18]\]) comprising 130,854 diabetic patients (11,781 in the treatment and 119,073 in the control group) were included in the final meta-analysis (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of the study selection process

Three studies \[[@CR12], [@CR15], [@CR17]\] examined the relationship between pioglitazone use and AF, while two other \[[@CR14], [@CR16]\] studied rosiglitazone use. The remaining two studies \[[@CR13], [@CR18]\] reported data regarding the use of pioglitazone, rosiglitazone and troglitazone. The characteristics of each study are listed in Table [2](#Tab2){ref-type="table"}, and the patients' characteristics in each study are shown in Table [3](#Tab3){ref-type="table"}.Table 2The characteristics of 7 included studiesStudy, yearStudy populationPatients (*n*)ComparatorsDaily dosage of TZDsFollow-upDefinition of AFMethods of AF detectionThe variables of multivariate modelPROactive, 2005 \[[@CR12]\]Patients with type 2 diabetes who had evidence of macrovascular disease5238Pioglitazone (*n* = 2605) vs. placebo (*n* = 2633)Titrated from 15 to 45 mg34.5 monthsNew-onset\
AFNANAAnglade, 2007 \[[@CR13]\]Diabetic patients who underwent CABG and/or valvular surgery184Pioglitazone (*n* = 14), rosiglitazone (*n* = 24) and troglitazone (*n* = 2) vs. No TZD (*n* = 140)Pioglitazone: average 30 mg\
Rosiglitazone: average 6 mg,\
Troglitazone: average 525 mg30 daysPostoperative AFNANARECORD, 2009 \[[@CR14]\]Patients with type 2 diabetes4447Rosiglitazone + metformin or sulfonylurea (*n* = 2220) vs. metformin and sulfonylurea (*n* = 2227)Titrated from 4 to 8 mg5.5 yearsNew-onset\
AFNANAGu, 2011Type 2 diabetic patients with paroxysmal AF undergoing catheter ablation161Pioglitazone (*n* = 51) vs. No pioglitazone (*n* = 99)30 mg22.9 ± 5.1 monthsRecurrent ATa (AF, AT, AFL)ECG and Holter recordingDuration of PAF, LAD, treatment with ACEI/ARBChao, 2012 \[[@CR16]\]Patients with non-insulin dependent diabetes.12,065Rosiglitazone (*n* = 4137) vs. No rosiglitazone (*n* = 7928)NA63 ± 25 monthsNew-onset AFNAAge, HTN, CAD, chronic renal disease and use of statins or alpha-glucosidase inhibitorsLiu, 2014 \[[@CR17]\]Diabetic patients with the first presence of persistent AF146Pioglitazone (*n* = 70) vs. placebo (*n* = 76)30 mg20.1 monthsRecurrent AFECG, history of arrhythmia-related symptoms, and Holter monitoringNAPallisgaard, 2016 \[[@CR18]\]Diabetic patients of Danish nationwide registries108,624TZD (*n* = 2658) vs. other second-line antidiabetic drugs (*n* = 105,966)NA12 yearsNew-onset\
AFNAAge, sex, stroke, HF, all cancer, hyperthyroidism, IHD, COPD, CKD, liver disease, vascular disease, HTN, statin use, prior CABG, and prior PCI*Abbreviations*: *AF* atrial fibrillation, *PAF* paroxysmal atrial fibrillation, *ATa* atrial tachyarrhythmias, *AT* atrial tachycardia, *AFL* atrial flutter, *ECG* electrocardiograph, *CABG* coronary artery bypass graft, *TZDs* thiazolidinediones, *LAD* left atrial diameter, *ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *HTN* hypertension, *CAD* coronary arterial disease, *IHD* ischaemic heart disease, *COPD* chronic obstructive pulmonary disease, *CKD* chronic kidney disease, *PCI* percutaneous coronary intervention, *NA* not applicable Table 3Patients characteristics of 7 included studiesStudy, yearDesignAge (years)\
T/CMale\
T/CHF\
T/CHTN\
T/CCAD\
T/CHbA1c (%) T/Cβ-blocker\
T/CCCB\
T/CACEI/ARB\
T/CStatin\
T/CInsulin\
T/CPROactive, 2005 \[[@CR12]\]RCT61.9/61.667%/66%NA75%/76%48%/48%7.8/7.955%/54%34%/37%70%/70%43%/43%33.2%/34%Anglade, 2007 \[[@CR13]\]Nested case control study of patients from the AFIST I, II and III trials65.8/67.272.5%/71.5%15.0%/18.8%90.0%/75.7%NANA75.0%/75.0%12.5%/21.5%75.0%/56.9%77.5%/61.8%NARECORD, 2009 \[[@CR14]\]RCT58.4/58.551.4%/51.7%0.5%/0.4%NANA7.9/7.922.6%/20.9%19.1%/21.6%43.1%/42.1%18%/19.2%NAGu, 2011Prospective cohort study59.6/58.752.9%/45.5%0/062.7%/72.7%5.9%/5.1%6.2/6.435.3%/37.4%35.3%/28.3%56.9%/45.5%13.7%/12.1%3.9%/2.0%Chao, 2012 \[[@CR16]\]Nested case control study of patients from NHIRD53.7/54.152.9%/53.6%4.1%/4.7%38.1%/44.5%16.9%/18.4%NA45.5%/46.4%NA68.6%/68.3%59%/57.4%0/0Liu, 2014 \[[@CR17]\]RCT60.70/62.2574.3%/ 65.8%0/028.6%/30.3%28.6%/30.3%6.41/6.1941.4%/38.2%20%/17.1%NA31.4%/34.2%NAPallisgaard, 2016 \[[@CR18]\]Prospective cohort study59.59/62.4056.7%/ 58.1%2.3%/4.9%50.2%/48.4%NANA31.5%/31.5%NA58.8%/55.9%58.0%/53.0%NA*Abbreviations*: *RCT* randomized controlled trial, *HF* heart failure, *HTN* hypertension, *CAD* Coronary arterial disease, *HbA1c* haemoglobin A1c, *CCB* calcium channel blocker, *ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *T/C* thiazolidinediones group/control group, *NA* not applicable

Of the seven studies, four \[[@CR15]--[@CR18]\] studies showed that TZDs use attenuated either the risk of new-onset or recurrent AF, whereas the other three \[[@CR12]--[@CR14]\] studies did not indicate a statistically significant difference. Overall, the pooled analysis of the seven included studies suggested that patients treated with TZDs have nearly 30% lower risk of AF compared with controls (OR =0.73, 95% CI = 0.62--0.87, *p* = 0.0003; Fig. [2](#Fig2){ref-type="fig"}). No significant heterogeneity between the individual studies was observed (*P* = 0.36, I^2^ = 9%).Fig. 2Forest plot showing the association association between thiazolidinediones (TZDs) and atrial fibrillation (AF)

Subgroup analyses according to AF types, different TZDs, follow-up duration, and study designs were subsequently performed (Fig. [2](#Fig2){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). TZDs use was associated with a decrease in the risk of both new-onset \[[@CR12], [@CR14], [@CR16], [@CR18]\] (OR =0.77, 95% CI = 0.65--0.91, *p* = 0.002) and recurrent AF \[[@CR13], [@CR15], [@CR17]\] (OR =0.41, 95% CI = 0.24--0.72, 0.002) without any heterogeneity across the studies. Regarding different TZDs, pioglitazone use \[[@CR12], [@CR15], [@CR17]\] (OR =0.56, 95% CI = 0.32--0.98, *p* = 0.04; I^2^ = 54%) was associated with a lower risk of AF incidence, whereas rosiglitazone use \[[@CR14], [@CR16]\] was not significantly associated with a decreasing AF incidence (OR =0.78, 95% CI = 0.57--1.07, *p* = 0.12; I^2^ = 34%). Regarding the subgroup analysis on different follow-up duration, there was no significant difference between the 3 studies \[[@CR14], [@CR16], [@CR18]\] with a follow-up duration \>5 years (OR =0.76, 95% CI = 0.63--0.91, *p* = 0.002; I^2^ = 0%) and the 4 studies \[[@CR12], [@CR13], [@CR15], [@CR17]\] with a follow-up duration ≤5 years (OR =0.62, 95% CI = 0.41--0.94, *p* = 0.02; I^2^ = 34%). Finally, the pooled analysis of the 4 \[[@CR13], [@CR15], [@CR16], [@CR18]\] observational studies showed a strong association between TZDs use and risk reduction of AF (OR =0.71, 95% CI = 0.59--0.85, *p* = 0.0003; I^2^ = 0%), whereas the pooled analysis of the three RCTs showed a non-statistically significant 23% reduction in the odds of developing AF (OR =0.77, 95% CI = 0.53--1.12, *p* = 0.10; I^2^ = 40%).Table 4Subgroup analyses of the association between TZDs and AFSubgroupStudyNumber of studiesHeterogeneityMeta-analysisI^2^*P*-ValueOR95% CI*p*-ValueAF typesNew-onset AF40%0.640.770.65--0.910.002Recurrent AF20%0.540.410.24--0.720.002TZDsSolely pioglitazone354%0.110.560.32--0.980.04Solely rosiglitazone234%0.220.780.57--1.070.12Follow-up duration≤ 5 years434%0.210.620.41--0.940.02\> 5 years300.470.760.63--0.910.002Study designRCTs340%0.100.770.53--1.120.17Observational studies40%0.410.710.59--0.850.0003*Abbreviations*: *TZDs* thiazolidinediones, *AF* atrial fibrillation, *RCTs* randomized controlled trials, *OR* odds ratio, *CI* confidence interval

Besides, due to different pathophysiologic mechanisms of AF, a sensitivity analysis was performed by removing the studies evaluated post-operation AF \[[@CR13]\] and post-AF \[[@CR15]\] ablation recurrences, no significant differences were found in the heterogeneity (*P* = 0.44; I^2^ = 0%) among the remaining five studies \[[@CR12], [@CR14], [@CR16]--[@CR18]\], and the overall outcome remained the same (OR =0.75, 95% CI = 0.64--0.88, *p* = 0.0003).

Discussion {#Sec8}
==========

The main findings of this comprehensive meta-analysis on 130,854 diabetic patients are the following: i. TZDs may confer protection against AF incidence; ii. the beneficial effects of TZDs were consistently observed in both new onset and recurrent AF; iii. Pioglitazone use was associated with a statistically reduced risk of incident AF, whereas rosiglitazone use showed no statistically significant difference; and iv. the protective effects of TZDs were only observed in the pooled analysis of the observational studies rather than the RCTs.

The PROactive \[[@CR12]\] and RECORD \[[@CR14]\] RCTs showed that pioglitazone or rosiglitazone use does not provide any benefit in preventing AF incidence among high-risk patients with type 2 DM. However, in these two RCTs, AF was reported as an adverse event rather than a predefined endpoint. Furthermore, these trials displayed a very low AF incidence in both intervention and control groups (1.5--2%), and thus AF detection may be underpowered.

Moreover, in the present meta-analysis, we observed that pioglitazone use was associated with beneficial effects on AF prevention compared with rosiglitazone use. Similarly, previous study suggested that pioglitazone has a beneficial effect on cardiovascular disease, whereas rosiglitazone seemed to increase cardiovascular risk \[[@CR24]\]. By assembling a diabetic cohort of older than 65 years, Winkelmayer et al. \[[@CR25]\] demonstrated greater risk of mortality and congestive heart failure among patients who initiated therapy with rosiglitazone compared with pioglitazone, however, there were no differences in their incidences of myocardial infarction or stroke. Previous data \[[@CR26]\] also showed similar effects on glycemic control between pioglitazone and rosiglitazone, as well as on other parameters such as C-reactive protein (CRP), plasminogen activator inhibitor-1 and indices of insulin secretion and sensitivity. However, pioglitazone treatment was associated with greater beneficial changes on plasma lipids than rosiglitazone treatment \[[@CR26]\], which may partly explain the advantage of pioglitazone in reducing AF incidence.

Recently, the IRIS trial \[[@CR27]\] demonstrated that pioglitazone can prevent fatal or nonfatal stroke or myocardial infarction among patients who have insulin resistance along with cerebrovascular disease. However, the underlying mechanism for these beneficial effects of pioglitazone remains incompletely elucidated. AF is a known risk factor of morbidity and mortality by predisposing to strokes and acute coronary syndrome \[[@CR28]\]. Thus, it is possible to postulate that pioglitazone reduces the stroke or MI events partly through the reduction of AF burden.

Accumulating evidence supports the role of inflammation and immune response activation in the genesis and perpetuation of AF in different clinical settings, including cardiac surgery, electrical cardioversion and catheter ablation \[[@CR29]\]. Oxidative stress has been suggested to play an important role in AF incidence \[[@CR30]\]. Numerous studies have demonstrated that TZDs may attenuate inflammation and oxidative stress as well as atrial electrophysiological and structural remodeling in different animal models.

In a ventricular tachypacing-induced CHF rabbit model, Shimano et al. \[[@CR31]\] showed that pioglitazone prevents atrial structural remodeling and inhibits AF promotion. Also, similarly to candesartan, pioglitazone suppresses transforming growth factor-β1 (TGF-β1) and tumor necrosis factor-α (TNF-α) expression in atrial tissue, molecules that are inflammatory mediators related to fibrosis-mediated AF incidence \[[@CR29]\]. More recently, Kume et al. \[[@CR32]\] suggested that pioglitazone effectively attenuates inflammatory profibrotic signals and vulnerability to AF in a pressure overload AF rat model, possibly via its suppression in monocyte chemoattractant protein (MCP-1) expression. PPAR-γ agonists have been shown to attenuate Angiotensin II (Ang II) -induced atrial electrical and structural remodeling in cellular models \[[@CR33]\]. These effects are mediated by prevention of ICa-L remodeling by inhibiting CAMP responsive element binding protein (CREB) phosphorylation, as well as by suppression of connective tissue growth factor (CTGF) expression and cell proliferation via inhibiting TGF-β1/Smad2/3 and TGF-β1/tumor necrosis factor receptor associated factor 6 (TRAF6)/TGF-β-associated kinase 1 (TAK1) signaling pathways. In addition, Pioglitazone exhibits beneficial effects on Ang II-induced potassium channel remodeling \[[@CR34]\]. More recently, Chen et al. \[[@CR35]\] further indicated that pioglitazone inhibits Ang II-induced atrial fibroblasts proliferation through nuclear factor-κB (NF-κB)/TGF-β1/Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF)/TRAF6 signaling pathway. Additionally, Xu et al. \[[@CR36]\] suggested that pioglitazone prevents age-related arrhythmogenic atrial remodeling and AF incidence by improving heat shock protein (HSP) 70 expression and antioxidant capacity, and by inhibiting the mitochondrial apoptotic signaling pathway. In an alloxan-induced diabetic rabbit model, we have shown that rosiglitazone attenuates arrhythmogenic atrial structural remodeling and AF incidence via anti-inflammatory and antioxidant effects \[[@CR37]\]. In keeping with these findings, the IRIS trial found lower CRP levels in the pioglitazone group than in the placebo group. Indeed, increased CRP levels have been associated with greater risk of AF \[[@CR38]\].

Finally, the treatment of hyperglycemia may have favorable effects on AF burden. In other words, treatment of DM may ameliorate atrial remodeling \[[@CR7]\]. Haemoglobin A1c levels have been associated with the occurrence and recurrence of AF \[[@CR7], [@CR39], [@CR40]\], and therefore TZDs may exert their favorable effects through HbA1c level reduction.

Study limitations {#Sec9}
-----------------

The present meta-analysis has potential limitations. Firstly, due to the small number of included studies we analyzed observational studies and RCTs together while 2 included RCTs reported AF as an adverse event rather than a predefined endpoint, and the favorable effects of TZDs use on preventing AF incidence were predominately driven by observational studies, whereas data from the 2 RCTs were unable to draw unanimous conclusion. Secondly, information regarding methods of AF detection, cardiac substrate, ejection fraction and atrial volume were not fully presented in our analysis due to the lack of relative data. Thirdly, the heterogeneous types of patient populations (ranging from uncomplicated type 2 diabetics to post-CABG or post-AF ablation patients) may indicate latent bias in this meta-analysis. Fourthly, "gray" literature (primarily conference abstracts/presentations, ongoing studies, communication with investigators) was not searched. Finally, the results of the funnel plot suggested that publication bias may be present, although the small number of studies made this somewhat difficult to interpret (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Funnel plot of meta-analysis

Conclusions {#Sec10}
===========

In summary, this meta-analysis suggests that TZDs may be effective in AF prevention in the setting of DM. Therefore, TZDs may be considered as the treatment of choice in diabetic patient with high risk features for AF incidence. Since the overall conclusion was mainly drawn from the observational studies, further large-scale prospective RCTs that assessed AF as a predefined outcome are needed to determine whether TZDs use could prevent AF in the setting of DM.
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